Cargando…
Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation
The WHO classifies t(6;9)-positive acute myeloid leukemia (AML) as a subgroup of high-risk AML because of its clinical and biological peculiarities, such as young age and therapy resistance. t(6;9) encodes the DEK/NUP214 fusion oncoprotein that targets only a small subpopulation of bone marrow proge...
Autores principales: | Chiriches, Claudia, Nicolaisen, Nathalie, Wieske, Maria, Elhaddad, Heba, Mehmetbeyoglu, Ecmel, Alvares, Caroline, Becher, Dörte, Hole, Paul, Ottmann, Oliver Gerhard, Ruthardt, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639852/ https://www.ncbi.nlm.nih.gov/pubmed/36288392 http://dx.doi.org/10.1371/journal.pgen.1010463 |
Ejemplares similares
-
Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia
por: Chiriches, Claudia, et al.
Publicado: (2022) -
P546: MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Elhaddad, Heba, et al.
Publicado: (2023) -
P456: LEUKEMOGENESIS BY AML-SPECIFIC DRIVER MUTATIONS WITHIN DNMT3A, IDH2 AND NPM1
por: Mehmetbeyoglu, Ecmel, et al.
Publicado: (2023) -
Molecular Systems Architecture of Interactome in the Acute Myeloid Leukemia Microenvironment
por: Ayyadurai, V. A. Shiva, et al.
Publicado: (2022) -
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)